Contineum Therapeutics Inc
CTNM
查看详细走势图
15.000USD
+0.520+3.59%
收盘 02/06, 16:00（美东）报价延迟15分钟
437.74M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.59%
5天
+5.19%
1月
+56.90%
6月
+122.88%
今年开始到现在
+31.23%
1年
+78.36%
查看详细走势图
TradingKey Contineum Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Contineum Therapeutics Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名17/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价20.33。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Contineum Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Contineum Therapeutics Inc亮点
亮点风险
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
业绩转亏
公司业绩转亏，最新年度亏损美元
估值低估
公司最新PE估值-6.65，处于3年历史低位
机构加仓
最新机构持股17.77M股，环比增加0.03%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值1.29K
分析师目标
根据
7
位分析师
买入
评级
20.333
目标均价
+37.39%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Contineum Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Contineum Therapeutics Inc简介
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.
公司代码CTNM
公司Contineum Therapeutics Inc
CEOStengone (Carmine)
网址https://www.contineum-tx.com/
相关品种
